

Attorney's Docket No. 011900-310  
Application Serial No. 09/903,734  
Page 2

CLAIM SUMMARY DOCUMENT:

1. (Currently Amended) An A synergistic inhibitor composition of *Helicobacter pylori* adhesion in the gastrointestinal tract of a mammal, consisting essentially of including humans, comprising (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated *Helicobacter pylori* urease, wherein said IgY antibodies are capable of specifically binding to the adhesion portion of *Helicobacter pylori* urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H<sub>2</sub> blockers and proton pump inhibitors.
2. (Original) The inhibitor composition according to Claim 1, wherein the IgY antibodies are isolated and purified antibodies.
3. (Currently Amended) A pharmaceutical composition for preventing and/or treating a disease caused by or associated with *Helicobacter pylori* in a mammal, consisting essentially of: including humans, comprising a pharmaceutically effective amount of the a synergistic inhibitor composition consisting essentially of comprising (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated *Helicobacter pylori* urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H<sub>2</sub> blockers and proton pump inhibitors, inhibitors; and

(05/03)

Attorney's Docket No. 011900-310  
Application Serial No. 09/903,734  
Page 3

a pharmaceutically acceptable carrier or diluent.

*C1  
cont'*

4. (Original) The pharmaceutical composition according to Claim 3, wherein the IgY antibodies are isolated and purified antibodies.

*C7*

5. (Currently Amended) A method for inhibiting *Helicobacter pylori* adhesion in a mammal including humans, comprising orally administering to the mammal an inhibitor composition in an effective amount for inhibiting *Helicobacter pylori* adhesion, which composition comprises consists essentially of (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated *Helicobacter pylori* urease, wherein said IgY antibodies are capable of specifically binding to the adhesion portion of *Helicobacter pylori* urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H<sub>2</sub> blockers and proton pump inhibitors an inhibitor of gastric acid secretion.

6. (Currently Amended) A method for preventing and/or treating a disease caused by or associate with *Helicobacter pylori* in a mammal including humans, comprising orally administering to the mammal an inhibitor composition in an effective amount for preventing or treating the disease, which composition comprises consists essentially of (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated *Helicobacter pylori* urease,

(05/03)

Attorney's Docket No. 011900-310Application Serial No. 09/903,734

Page 4

wherein said IgY antibodies are capable of specifically binding to the adhesion portion of  
*Helicobacter pylori* urease in the gastrointestinal tract of the mammal, and (2) at least one  
agent selected from H<sub>2</sub> blockers and proton pump inhibitors an inhibitor of gastric acid  
secretion.

*CP*  
*cont*

*C3*

5. (New) The inhibitor composition according to Claim 1, wherein the mammal is a human.

6. (New) The pharmaceutical composition according to Claim 3, wherein the mammal is a human.

(05/03)